Humacyte, Inc. (HUMA)
0.6816
-0.02
(-2.80%)
USD |
NASDAQ |
Aug 26, 16:00
0.6852
0.00 (0.00%)
After-Hours: 20:00
Humacyte Shareholders Equity (Quarterly) : 31.26M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.26M |
| March 31, 2026 | 11.62M |
| December 31, 2025 | 3.109M |
| September 30, 2025 | -4.751M |
| June 30, 2025 | 4.052M |
| March 31, 2025 | 36.04M |
| December 31, 2024 | -52.67M |
| September 30, 2024 | -63.72M |
| June 30, 2024 | -28.29M |
| March 31, 2024 | 26.15M |
| December 31, 2023 | 13.55M |
| September 30, 2023 | 36.99M |
| Date | Value |
|---|---|
| June 30, 2023 | 61.12M |
| March 31, 2023 | 81.89M |
| December 31, 2022 | 116.93M |
| September 30, 2022 | 118.67M |
| June 30, 2022 | 142.26M |
| March 31, 2022 | 103.89M |
| December 31, 2021 | 122.17M |
| September 30, 2021 | 75.86M |
| June 30, 2021 | 83.70M |
| March 31, 2021 | 83.41M |
| December 31, 2020 | 70.67M |
| September 30, 2020 | 99.36M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Amgen, Inc. | 11.69B |
| Altimmune, Inc. | 474.21M |
| Protalix Biotherapeutics, Inc. | 71.40M |
| Taysha Gene Therapies, Inc. | 387.27M |
| Agenus, Inc. | -199.08M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 138.09M |
| Total Liabilities (Quarterly) | 106.83M |
| Debt to Equity Ratio | 2.117 |
| Current Ratio | 6.207 |
| Net Debt Paydown Yield | 1.48% |